Immunopharmacological Interventions in Select Disease Conditions
DOI:
https://doi.org/10.47672/ejhs.2693Keywords:
Immunology, Immunotherapy, Immune Response, Hypertension, Diabetes, TumourAbstract
Purpose: Medical practitioners have grappled with the challenge encountered with management of several diseases especially diseases that cannot be cured but can only be managed. In the course of therapy, some patients stop getting positive results from previously efficacious drug while adverse effects of some drugs become unbearable in time. This study aims at bringing together immunotherapeutic approaches that could be researched upon, and presented for clinical trials for the betterment of patients’ lives.
Materials and Methods: SALSA, a simple and rational framework (Search, Appraisal, Synthesis and Analysis) was adopted in the study. Only studies on immunology and immunotherapy were included. By applying the framework of SALSA, the first step was to search or to identify relevant and related studied. For this purpose, different search engines that include Google Scholar, Web of Science and Scopus were used. Different key words such as immunology, immunotherapy, immune response, hypertension, diabetes, tumour, etc. were used in the search for relevant studies. After downloading the studies, a manual appraisal was done to remove irrelevant and duplicated ones. In the end, 105 studies that align with our research objectives was selected and reviewed.
Findings: Hypertension was ranked the third factor for disability-adjusted life years by World Health Organisation. For over 40 years, the role of immune system in the genesis of HTN has been firmly established by investigations from around the world. Researchers have pinned inflammation as central to the pathology of Type 1 disease. Type 2 diabetes has more recently been linked to inflammation too. Natural Killer cells along with some others have the ability to kill tumour cells. Since the immune system has been implicated in the pathogenesis of these diseases, any therapy that would target the immune system may ameliorate and prevent disease progression and the usual complications that ensue later.
Unique Contribution to Theory, Practice and Policy: Further investigations utilising well-designed and statistically powered clinical studies should be done to ascertain necessary information, especially safety profile on the reviewed immunomodulators.
Downloads
References
Al-Razi. (2003). The Columbia Electronic Encyclopedia, 6th ed. Columbia University Press.
American Diabetes Association. Screening for type 2 diabetes. Diabetes Care, v. 26, p. S21-S24, 2003.
Arestides, R. S. S, He, H., Westlake, R. M., Chen, A. L., Sharpe A. H., Perkins, D. L. and Finn, P. W. (2002). Costimulatory molecule OX40L is critical for both Th1 and Th2 responses in allergic inflammation. European Journal of Immunology, 32:2874–2880.
Banerjee, M. and Saxena M. (2014). Genetic polymorphisms of cytokine genes in type 2 diabetes mellitus. World journal of Diabetes, 5: 493-504.
Bartkowiak, T. and Curran, M. A. (2015). 4-1BB agonists: multi-potent potentiators of tumor immunity. Frontiers in Oncology, 5: 117.
Baumann, R., Yousefi, S., Smon, D., Russman, S., Mueller, C. and Simon, H. (2004). Functional expression of CD134 by neutrophils. European Journal of Immunology, 34: 2268–2275.
Brahmer, J., Reckamp, K. L., Baas, P. and Crno, L. (2015). Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. New England Journal of Medicine, 373:123–134.
Bravo, Y., Quiroz, Y. and Ferrebuz, A. (2007). Mycophenolate mofetil administration reduces renal inflammation, oxidative stress, and arterial pressure in rats with lead-induced hypertension. American Journal of Physiology - Renal Physiology, 293: F616-F623.
Burington, B., Riviere, I., Park, J. H. and Davilla, M.L. (2011). CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphoma. Science Translational Medicine, 3:74ra22.
Candeias, S. M. and Gaipl, U. S. (2016). The immune system in cancer prevention, development and therapy. Anticancer Agents in Medicinal Chemistry, 16(1): 101-7.
Cavelti-Weder, C., Babians-Brunner, A., Keller, C., Stahel, M. A., Kurz-Levin, M., Zayed, H. and Solinger, A. M. (2012). Effects of gevokizumab on glycaemia and inflammatory markers in type 2 diabetes. Diabetes Care, 35: 1654-1662.
Chemnitz, J. M., Parry, R. V., Nichols K. E., June, C. H. and Riley, J. L. (2004). SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. Journal of Immunology, 173: 945-954.
Chen, Y. M., Lin, C. H., Lan, T. H., Chen, H. H., Chang, S. N., Chen Y. H., Wang, J. S., Hung, W. T., Lan, J. L. and Chen, D. Y. (2015). Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose-dependent manner: a population-based cohort study. Rheumatology, 54: 1244-1249.
Cohen, A. D., Schaer, D. A., Liu, C., Li, Y., Hirschhorn-Cymmerman, D., Kim, S. C., Diab, A., Rizzuto, G., Duan, F., Perales, M. A., Merghoub, T., Houghton, A. N. And Wolchok, J. D. (2010). Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLOS ONE, 5: e10436.
Curran, M. A., Kim, M., Montalvo, W., Al-Shamkhani, A. And Allison, J. P. (2011). Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLOS ONE, 6: e19499.
Curti, B. D., Kovacsovics-Bankowski, M., Morris, N., Walker, E., Chisholm, L., Floyd, K., Walker, J., Gonzalez, I., Meeuwsen, T., Fox, B. A., Moudgil, T., Miller, W., Haley, D., Coffey, T., Fisher, B., Delanty-Miller, L., Rymarchyk, N., Kelly, T., Crocenzi, T., Bernstein, E., Sanborn, R., Urba, W. J. andWeinberg, A. D. (2013). OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Research, 73:7189–7198.
Dharanidharan Ramamurthy, D., Nundalall, T., Cingo, S., Mungra, N., Karaan, M., Naran, K. and Barth, S. (2020). Recent advances in immunotherapies against infectious diseases. Immunotherapy Advances, 1(475): 1-27.
Dinarello C.A. (1996). Biologic basis for interleukin-1 in disease. Blood, 87(6): 2095-2147.
Dominguez, H., Storgaard, H., Rask-Madsen, C., Steffen Hermann, T., Ihlemann, N., Baunbjerg, N. D., Spohr, C., Kober, L., Vaag, A. and Torp-Pedersen, C. (2005). Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. Journal of Vascular Research, 42: 517-525.
Dragun, D., Müller, D. N., Bräsen, J. H., Fritsche, L., Nieminen-Kelhä, M., Dechend, R., Kintscher, U., Rudolph, B., Hoebeke, J. and Eckert, D. (2005). Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. New England Journal of Medicine, 352: 558-569.
Dunn, G. P., Old, L. J. and Schreiber, R. D. (2004). The immunobiology of cancer immunosurveillance and immunoediting. Immunity, 21(2): -148.
Emami, J., Pasutto, F. M., Mercer, J. R. and Jamali F. (1999). Inhibition of insulin metabolism by hydroxychloroquine and its enantiomers in cytosolic fraction of liver homogenates from healthy and diabetic rats. Life Sciences, 64: 325-335.
Fu, M.L., Herlitz, H., Schulze, W., Wallukat, G., Micke, P., Eftekhari, P., Sjögren, K. G., Hjalmarson, A., Müller-Esterl, W. and Hoebeke, J. (2000). Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension. Journal of Hypertension, 18: 945-953.
Fucikova, J., Truxova, I., Hensler, M., Becht, E., Kasikova, L., Moserova, I., Vosahlikova, S., Klouckova, J., Church, S. E., Cremer, I., Kepp, O., Kroemer, G., Galluzzi, L. Salek, C. and Spisek, R. (2016). Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients. Blood, 128(26): 3113–3124.
Gherardi, E. (from Answers.com, 2006). The concept of immunity, history and applications. Immunology course medical school, University of Pavia. The Columbia Electronic Encyclopedia, 6th ed. Columbia University Press.
Goldfine, A. B., silver, R., Aldhahi, W., Cai, D., Tatro, E., lee, J. and Shoelson, S. (2008). Use of salsalate to target inflammation in the treatment of insulin, resistance and type 2 diabetes. Clinical and Translational Science, 1(1): 36-43.
Grant, M. J., and Booth, A. (2009). A typology of reviews: An analysis of 14 review types and associated methodologies. Health Information & Libraries Journal, 26(2), 91-108.
Greenberg, S. (n.d.). A concise history of immunology. Available at: https://www.studocu.com/in/document/university-of-allahabad/bachelor-of-science/concise-history-immunology/49624130
Guzik, T. J., Hoch, N. E. and Brown, K. A. (2007). Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. Journals of Experimental Medicine, 204: 2449-2460.
Hanahan, D. and Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144(5): 646-74.
Harrison, D.G., Guzik, T.J., Lob, H.E., Madhur, M.S., Marvar, P.J., Thabet, S.R., Vinh, A., Weyand, C.M. (2011). Inflammation, immunity, and hypertension. Hypertension, 57(2):132-40.
Herrera, J., Ferrebuz, A. and Macgregor, E. G. (2006). Mycophenolate mofetil treatment improves hypertension in patients with psoriasis and rheumatoid arthritis. The Journal of the American Society of Nephrology, 17: S218-S225.
Hodge, J. W., Garnett, C. T., Farsaci, B., Palena, C., Tsang, K. Y., Ferrone, S. and Gameiro, S. R. (2013). Chemotherapy induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. International Journal of Cancer, vol. 133, no. 3, pp. 624–636.
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., Akerley, W., van den Eertwegh, A. J., Lutzky, J., Lorigan, P., Vaubel, J. M., Linette, G. P., Hogg, D., Ottensmeier, C. H., Lebbé, C., Peschel, C., Quirt, I., Clark, J. I., Wolchok, J. D., Weber, J. S., Tian, J., Yellin, M. J., Nichol, G. M., Hoos, A. and Urba, W. J. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine, 363: 711-723.
Hofstad, T., Hampton, J.A. and Hofmann, B. (2020). What Makes Some Diseases More Typical than Others? A Survey on the Impact of Disease Characteristics and Professional Background on Disease Typicality. Inquiry: The Journal of Health Care Organization, Provision, and Financing, 57: 1-9.
Hotamisligil, G. S., Shargill, N. S., Spiegelman, B. M. (1993). Adipose expression of tumor necrosis factoralpha: Direct role in obesity-linked insulin resistance. Science, 259:87–91.
International Diabetes Federation. IDF Diabetes Atlas, 7 ed. Brussels, Belgium, International Diabetes Federation, 2015.
Kochenderfer, J. N., Dudley, M. E., Kassim, S. H., Somerville, R. P., Carpenter, R. O., Stetler-Stevenson, M., Yang, J. C., Phan, G. Q., Hughes, M. S., Sherry, R. M., Raffeld, M., Feldman, S., Lu, L., Li, Y. F., Ngo, L. T., Goy, A., Feldman, T., Spaner, D. E., Wang, M. L., Chen, C. C., Kranick, S. M., Nath, A., Nathan, D. A., Morton, K. E., Toomey, M. A. and Rosenberg, S. A. (2015). Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. The Journal of Clinical Oncology, 33: 540-549.
Karlitepe, A., Ozalp, O. and Avci, C. B. (2015). New approaches for cancer immunotherapy. Tumor Biology, 1-4.
Kawabe, T., Naka, T., Yoshida, K., Tanaka, T., Fujiwara, H., Suematsu, S., Yoshida, N., Kishimoto, T. and Kikutani, H.(1994). The immune responses in CD40-deficient mice: Impaired immunoglobulin class switching and germinal center formation. Immunity, 1:167–178.
Khalil, D. N., Budhu, S., Gasmi, B., Zappasodi, R., Hirschhorn-Cymerman, D., Plitt, T., De Henau, O., Zamarin, D., Holmgaard, R. B., Murphy, J. T., Wolchok, J. D. and Merghoub, T.(2015). The new era of cancer immunotherapy: manipulating T-cell activity to overcome malignancy. Advances in Cancer Research, 128:1-68.
Khan, A., Khan, I., Sulemanm, Zahid, K., Nabi, G. (2015). A comprehensive review on various aspects of genetic disorders. Journal of Biology and Life Science, 6 (2): 110-118.
Köhl, J. (2006). Self, non-self, and danger: a complementary view. Advances in Experimental Medicine and Biology, 586:71-94.
Kozlov, V. A. (2016). Suppressor cells - the basis of the immunopathogenesis of cancer. Voprosy Onkologii., 62(3): 390 - 6.
Kriska, T., Cepura, C., Magier, D., Siangjong, L., Gauthier, K. M. and Campbell, W. B. (2012). Mice lacking macrophage 12/15-lipoxygenase are resistant to experimental hypertension. American Journal of Physiology - Heart and Circulatory Physiology. 302.
Krummel, M. F. and Allison, J. P. (1995). CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. Journal of Experimental Medicine, 182:459–465.
Larsen, C. M., Faulenbach, M., Vaag, A., Ehses, J. A., Donath, M. Y. and Mandrup-Poulsen, T. (2009). Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care, 32: 1663–1668.
Laura, H., Goetz, L.H. and Schork, N.J. (2019). Personalized medicine: Motivation, challenges and progress. Fertility and Sterility, 109(6):952-963.
Lee, D. W, Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., Steinberg, S. M., Stroncek, D., Tschernia, N., Yuan, C., Zhang, H., Zhang, L., Rosenberg, S. A., Wayne, A. S. and Mackall, C. L.(2015). T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. The Lancet, 385:517–528.
Lee, H. W., Park, S. J., Choi, B. K., Kim, H. H., Nam, K. O. and Kwon, B. S. (2002). 4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1. Journal of Immunology, 169:4882–4888.
Londrigan, S. L., Sutherland, R. M., Brady, J. L., Carrington, E. M., Cowan, P. J., d'Apice, A. J., O'Connell, P. J., Zhan, Y. and Lew, A. M. (2010). In situ protection against islet allograft rejection by CTLA4Ig transduction. Transplantation, 90:951–957.
Lu, X., Ding, Z. C., Cao, Y., Liu, C., Habtetsion, T., Yu, M., Lemos, H., Salman, H., Xu, H., Mellor, A. L. and Zhou, G. (2015). Alkylating agent melphalan augments the efficacy of adoptive immunotherapy using tumor specific CD4+ T cells. The Journal of Immunology, vol. 194, no. 4, pp. 2011–2021.
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P.A. and Donath, M. Y. (2002). Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. Journal of clinical Investigation, 110: 851–860.
Matsushita, H., Yahata, T., Sheng, Y., Nakamura, Y., Muguruma, Y., Matsuzawa, H., Tanaka, M., Hayashi, H., Sato, T., Damdinsuren, A., Onizuka, M., Ito, M., Miyachi, H., Pandolfi, P.P. and Ando, K. (2014). Establishment of a humanized APL Model via the transplantation of PML-RARA-transduced human common myeloid progenitors into immunodeficient mice. PLOS One, 9(11): 1-12.
McClurkey, K. (2016). Immunotherapy vs Chemotherapy: What’s the difference? A Publication of Cancer Research Institute, New York.
McCurley, A., Pires, P. W., Bender, S. B., Aronovitz, M., Zhao, M. H., Metzger, D., Chambon, P., Hill, M. A., Dorrance, A. M., Mendelsohn, M. E. and Jaffe, I. Z. (2012). Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nature Medicine, 18: 1429-1433.
Meddah, B., Ducroc, R., El Abbes Faouzi, M., Eto, B., Mahraoui, L., Benhaddou-Andaloussi, A., Martineau, L. C., Cherrah, Y. andHaddad, P. S. (2009). Nigella Sativa inhibits intestinal glucose absorption and improves glucose tolerance in rats. Journal of Ethnopharmacology, v. 121, p. 419-24, 2009.
Moreau, P. (2017). How I treat myeloma with new agents. Blood, vol. 130, no. 13, pp. 1507–1513.
Morse, S.S. (2004). Factors and determinants of disease emergence. Revue Scientifique et Technique de l OIE, 23(2): 443-51.
Nava, M., Quiroz, Y., Vaziri, N. and Rodriguez-Iturbe, B.(2003). Melatonin reduces renal interstitial inflammation and improves hypertension in spontaneously hypertensive rats. American Journal of Physiology- Renal Physiology, 284: F447–F454.
Neimann, A. L., Shin, D. B., Wang, X. (2006). Prevalence of cardiovascular risk factors in patients with psoriasis. The Journal of the American Academy of Dermatology, 55: 829-835.
Norlander, A. E., Madhur, M. S., and Harrison, D. J. (2018). The immunology of hypertension. Journal of experimental Medicine, 215(1): 21-33.
Norlander, A. E., Saleh, M. A., Pandey, A. K., Itani, H. A., Wu, J., Xiao, L., Kang, J., Dale, B. L., Goleva, S. B., Laroumanie, F., Du, L., Harrison, D. G. and Madhur, M. S.(2017). A salt-sensing kinase in T lymphocytes, SGK1, drives hypertension and hypertensive end-organ damage. Journal of Clinical Investigation Insight, 2: 92801.
Oh, S., Shin, J. H., Jang, E. J., Won, H. Y, Kim, H. K., Jeong, M. G., Kim, K. S. and Hwang, E. S. (2016). Anti-inflammatory activity of chloroquine and amodiaquine through p21-mediated suppression of T cell proliferation and Th1 cell differentiation, Biochemical and Biophysical Research Communications, 474(2):345-350.
Okuda, T. and Grollman, A. (1967). Passive transfer of autoimmune induced hypertension in the rat by lymph node cells. Texas Report on Biology and Medicine, 25:257-264.
Pan, B. and Lentzsch, S. (2012). The application and biology of immunomodulatory drugs (IMiDs) in cancer. Pharmacology & therapeutics, 136(1): 56-68.
Pan, P. Y., Zang, Y., Weber, K., Meseck, M. L. and Chen, S. H.(2002). OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases. Molecular Therapy, 6:528–536.
Park, J. H., Rivière, I., Wang, X., Stefanski, J., He, Q., Taylor, C., Olszewska, M., Wasielewska, T., Bartido, S., Davila, M. L., Bernal, Y., Lamanna, N., Noy, A., Sadelain, M and Brentjens, R. J. (2012). Impact of the conditioning chemotherapy on outcomes in adoptive T cell therapy: results from a phase I clinical trial of autologous CD19-targeted T cells for patients with relapsed CLL. Blood, 120:1797.
Parry, R. V., Chemnitz, J. M., Frauwirth, K. A., Lanfranco, A. R., Braunstein, I., Kobayashi, S. V., Linsley, P. S., Thompson, C. B. and Riley, J. L. (2005). CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Molecular Cell Biology, 25:9543–9553.
Pavelka, K., Bruyère, O., Cooper, C., Kanis, J. A., Leeb, B. F., Maheu, E., Martel-Pelletier, J., Monfort, J., Pelletier, J., Rizzoli, R. and Reginster, J. (2016). Diacerein: Benefits, risks and place in the management of osteoarthritis. An opinion-based report from the ESCEO. Drugs & Aging; 33(2): 75-85.
Pollack, R. M., Donath, M. Y., LeRoith, D. and Leibowitz, G. (2016). Anti-inflammatory agents in the treatment of diabetes and its vascular complications. Diabetes Care, 39(2): S244–S252.
Quatraro, A., Consoli, G., Magno, M., Caretta, F. and Nardozza, A. (1990). Hydroxychloroquine in decompensated, treatment refractory noninsulin-dependent diabetes mellitus. A new job for an old drug? Annals of Internal Medicine, 112:678–681.
Ramos, C. A., Savoldo, B., Torrano, V., Ballard, B., Zhang, H., Dakhova, O., Liu, E., Carrum, G., Kamble, R. T., Gee, A. P., Mei, Z., Wu, M. F., Liu, H., Grilley, B., Rooney, C. M., Brenner, M. K., Heslop, H. E. and Dotti, G.(2013). Clinical responses in patients infused with T lymphocytes redirected to target κ-light immunoglobulin chain. Blood, 122:506.
Ramos-Zavala, M. G., Gonz ´alez-Ortiz, M., Mart´ınez-Abundis, E., Robles-Cervantes, J. A., Gonz ´alez, L. ´opez, R. and Santiago-Hern´andez, N. J. (2011). Effect of diacerein on insulin secretion and metabolic control in drug-naive patients with type 2 diabetes: a randomized clinical trial. Diabetes Care, 34:1591-1594.
Rang, H. P., Dale, M. M., Ritter, J. M. and Flower, R. T. (2007). Local hormones, Inflammation and immune reactions. In: Pharmacology. 6th ed. Elsevier, London. Pp 203–247.
Read, S., Malmström, V. and Powrie, F. (2005). Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25+CD4+ regulatory cells that control intestinal inflammation. Journal of Experimental Medicine, 192:295–302.
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, L., Carlino, M. S., McNeil, C., Lotem, M., Larkin, J., Lorigan, P., Neyns, B., Blank, C. U., Hamid, O., Mateus, C., Shapira-Frommer, R., Kosh, M., Zhou, H., Ibrahim, N., Ebbinghaus, S. and Ribas, A. (2015). Pembrolizumab versus ipilimumab in advanced melanoma. New England Journal of Medicine, 372: 2521-2532.
Rodríguez-Iturbe, B., Pons, H., Quiroz, Y., Gordon, K., Rincón, J., Chávez, M., Parra, G., Herrera-Acosta, J., Gómez-Garre, D., Largo, R. Egido, J. and Johnson, R. J. (2001). Mycophenolate mofetil prevents salt-sensitive hypertension resulting from angiotensin II exposure. Kidney International, 59:2222–2232.
Ronchetti, S., Nocentini, G., Bianchini, R., Krausz, L. T., Migliorati, G. and Riccardi, C. (2007). Glucocorticoid-induced TNFR-related protein lowers the threshold of CD28 costimulation in CD8+ T cells. Journal of Immunology, 179:5916–5926.
Schaer, D. A., Cohen, A. D. and Wolchok, J. D. (2010). Anti-GITR antibodies-potential clinical applications for tumor immunotherapy. Current Opinion in Investigational Drugs, 11:1378–1386.
Schaer, D. A., Budhu, S., Liu, C., Bryson, C., Malandro, N., Cohen, A., Zhong, H., Yang, X., Houghton, A. N., Merghoub, T. and Wolchok, J. D. (2013). GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability. Cancer Immunology Research, 1:320–331.
Schreiber, R. D., Old, L. J. and Smyth, M. J. (2011). Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science, 331(6024): 1565-1570.
Schroeder, T., Rautenberg, C., Haas, R., Germing, U. and Kobbe, G. (2018). Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation. International Journal of Haematology, vol. 107, no. 2, pp. 138–150.
Seaberg, E. C., Munoz, A. and Lu, M. (2005). Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS, 19:9 53-960.
Shojania, K., Koehler, B. E. and Elliott, T. (1999). Hypoglycemia induced by hydroxychloroquine in a type II diabetic treated for polyarthritis. The Journal of Rheumatology, 26: 195–196.
Shuford, W. W., Klussman, K., Tritchler, D. D., Loo, D. T., Chalupny, J., Siadak, A. W., Brown, T. J., Emswiler, J., Raecho, H., Larsen, C. P., Pearson, T. C., Ledbetter, J. A., Aruffo, A. and Mittler, R. S. (1997). 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. Journal of experimental Medicine, 1997; 186:47–55.
Siegel, R. L., Miller, K. D. and Jemal, A. (2015). Cancer statistics, 2015. A Cancer Journal for Clinicians, 65(1) 5-29.
Silverstein, A. M. (1989). History of immunology. London: Academic Press.
Sloan-Lancaster, J., Abu-Raddad, E., Polzer, J., Miller, J. W., Scherer, J. C., De Gaetano, A., Berg, J. K. and Landschulz, W. H. (2013). Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1b antibody, in patients with type 2 diabetes. Diabetes Care, 36: 2239-2246.
Svendsen, U. G. (1976). The role of thymus for the development and prognosis of hypertension and hypertensive vascular disease in mice following renal infarction. Acta Pathologica et Microbiologica Scandinavica [A], 84: 235–243.
Tian N., Gu J. W. and Jordan S. (2007). Immune suppression prevents renal damage and dysfunction and reduces arterial pressure in salt-sensitive hypertension. Amercan Journal of Physiology-Heart and Circulatory Physiology, 292: H1018–H1025.
Szuławska, A. and Czyz M. (2006). Molekularne mechanizmy działania antracyklin [Molecular mechanisms of anthracyclines action]. Postepy Higieny i Medycyny Doswiadczalnej, 60: 78-100.
Teng, M.W., Ngiow, S.F., Ribas, A., Smyth, M.J. (2015). Classifying cancers based on T-cell infiltration and PD-L1. Cancer Research, 75(11): 2139-2145.
Tooley, J. E., Waldron-Lynch, F. and Herold, K. C. (2012). New and future immunomodulatory therapy in type 1 diabetes. Trends in Molecular Medicine, 18(3): 173–181.
Triebel, F., Hacene, K. and Pichon, M. F. (2006). A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors. Cancer Letters, 235:147–153.
Turtle, C. J., Berger, C., Sommermeyer, D., Budiarto, T., Hanafi, L. and Melville, K. (2015). Immunotherapy with CD19-specific chimeric antigen receptor (CAR)-modified T cells of defined subset composition. Journal of Clinical Oncology, 33:3006.
Valzasina, B., Guiducci, C., Dislich, H., Killeen, N., Weinberg, A. D. and Colombo, M. P. (2005). Triggering of OX40 (CD134) on CD4+CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood, 105:2845–2851.
Vesely, M. D., Kershaw, M. H., Schreiber, R. D. and Smyth, M. J. (2011). Natural innate and adaptive immunity to cancer. Annual Review of Immunology, 29: 235-271.
Vinh, A., Chen, W., Blinder, Y., Weiss, D., Taylor, W. R., Goronzy, J. J., Weyand, C. M., Harrison, D. G. and Guzik, T. J. (2010). Inhibition and genetic ablation of the B7/CD28 T-cell costimulation axis prevents experimental hypertension. Circulation, 122: 2529-2537.
Vogel, T. J., Goodman, M. T., Li, A. J. and Jeon, C. Y. (2017). Statin treatment is associated with survival in a nationally representative population of elderly women with epithelial ovarian cancer. Gynecologic Oncology, 146 (2): 340–345.
Wahid, B., Ali, A., Rafique, S., Wakar, M. and Wasim, M. (2018). An overview of cancer immunotherapeutic strategies. Immunotherapy, 10(11): 999–1010.
Wallach, D. and Kang, T. (2018). Programmed cell death in immune defense: Knowledge and presumptions. Immunity, 49(1): 19-32.
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B. And Bluestone, J. A. (1994). CTLA-4 can function as a negative regulator of T cell activation. Immunity, 1:405-413.
Wang, D., Fu, J., Shi, Y., Peng, D.,Yuan, L., He, B., Dai, W., Zhang, H., Wang, X., Tian, J., Zhang, Q. (2016). The modulation of tumor vessel permeability by thalidomide and its impacts on different types of targeted drug delivery systems in a sarcoma mouse model. Journal of Controlled Release, 238: 186 -196.
White, F. N., and Grollman, A. (1964). Autoimmune factors associated with infarction of the kidney. Nephron, 1: 93-102.
WHO (2023, Sept 15). Non-communicable diseases. Available at https://www.who.int/teams/noncommunicable-diseases/hypertension-report
Wieder, T., Eigentler, T., Brenner, E., Röcken, M. (2018). Immune checkpoint blockade therapy. Journal of Allergy and Clinical Immunology, 142(5): 1403-1414.
Worboys, M. (2008). Spreading germs: Disease theories and medical practice in Britain, 1865-1900. Cambridge: Cambridge University Press.
Zeldis, J. B., Knight, R., Hussein, M., Chopra, R. and Muller, G. (2011). A review of the history, properties, and use of the immunomodulatory compound lenalidomide. Annals of the New York Academy of Sciences, 1222(1): 76-82.
Zhang, Z.L., Liu, Z.S., Sun, Q. (2005). Effects of Thalidomide on angiogenesis and tumor growth and metastasis of human hepatocellular carcinoma in nude mice. World Journal of Gastroenterology, 11(2): 216-220.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Ngozi Amanda Onwuka, Beatrice Imananagha-amene, Ucheawaji Felicia Edward, Nkechi Jovita Onyeukwu, Tamunobarabiye Ibifubara Nonju, Valentine Nwobuike Nnoka, Imaobong Ibifubara Nonju, Atuboyedia Wolfe Obianime
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
